Diagnostic of sensitivity mycobacterium tuberculosis strains to isoniazid and rifampicin by simultaneous identification of mutations in rpoB, katG, inhA and ahpC-oxyR genes with biological microchips Source: Eur Respir J 2006; 28: Suppl. 50, 379s Year: 2006
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Mutation analysis and treatment outcomes of Isoniazid monoresistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation Source: Eur Respir J, 50 (4) 1701752; 10.1183/13993003.01752-2017 Year: 2017
Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Relationship between rpoB mutations and minimum inhibitory concentrations of rifampicin in multi drug resistant strains of mycobacterium tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011
Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis. Source: International Congress 2017 – MDRTB: detection and management Year: 2017
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
Mutations of the gyrA gene of mycobacterium tuberculosis leading to XDR tuberculosis in Kyrgyz Republic Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013
Detection of fluoroquinolones resistance mutations in mycobacterium tuberculosis by hydrolysis probes and RFLP Source: Annual Congress 2013 –Diagnostic features of tuberculosis II Year: 2013
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary? Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019 Year: 2019
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
RpoB and katG mutations as an epidemiologic markers of multi-drug-resistant M. tuberculosis strains isolated in Kyrgyz Republic Source: Eur Respir J 2007; 30: Suppl. 51, 455s Year: 2007
Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006
Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003